Eli Lilly's antibody combination reduces risk of death from Covid-19 - study
Coronavirus chronicle
26 January, 2021, 06:00 pm
Last modified: 26 January, 2021, 06:05 pm
The results are from over 1,000 participants of the study, which is testing the combination of bamlanivimab and etesevimab
FILE PHOTO: The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, US, May 18, 2018. REUTERS/Brendan McDermid
Eli Lilly and Co said on Tuesday treatment with a combination of two of its antibodies helped reduce risk of hospitalizations and death due to Covid-19 by 70%, according to results from a late-stage trial.
The results are from over 1,000 participants of the study, which is testing the combination of bamlanivimab and etesevimab.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.